Nephrogenic diabetes insipidus
- PMID: 16580609
- DOI: 10.1053/j.ackd.2006.01.006
Nephrogenic diabetes insipidus
Abstract
Nephrogenic diabetes insipidus (NDI), which can be inherited or acquired, is characterized by an inability to concentrate urine despite normal or elevated plasma concentrations of the antidiuretic hormone arginine vasopressin (AVP). Polyuria, with hyposthenuria, and polydipsia are the cardinal clinical manifestations of the disease. About 90% of patients with congenital NDI are males with X-linked recessive NDI (OMIM 304800) who have mutations in the arginine-vasopressin receptor 2 (AVPR2) gene that codes for the vasopressin V2 receptor. In about 10% of the families studied, congenital NDI has an autosomal recessive or autosomal dominant mode of inheritance (OMIM 222000 and 125800). In these families, mutations have been identified in the aquaporin-2 gene (AQP2) (OMIM 107777), which codes for the vasopressin-sensitive water channel. Most missense AVPR2 mutations lead to receptors that are trapped intracellularly; a few mutant receptors reach the cell surface but are unable to bind AVP or to properly trigger an intracellular cyclic adenosine monophosphate signal. Similarly, most AQP2 mutant proteins are also misrouted. Prior knowledge of AVPR2 or AQP2 mutations in NDI families and perinatal mutation testing is of direct clinical value because early diagnosis and treatment can avert the physical and mental retardation associated with repeated episodes of dehydration.
Similar articles
-
V2R mutations and nephrogenic diabetes insipidus.Prog Mol Biol Transl Sci. 2009;89:15-29. doi: 10.1016/S1877-1173(09)89002-9. Epub 2009 Oct 7. Prog Mol Biol Transl Sci. 2009. PMID: 20374732 Review.
-
[Nephrogenic diabetes insipidus].Nephrol Ther. 2006 Nov;2(6):387-404. doi: 10.1016/j.nephro.2006.07.010. Epub 2006 Sep 25. Nephrol Ther. 2006. PMID: 17081961 Review. French.
-
Genetic forms of nephrogenic diabetes insipidus (NDI): Vasopressin receptor defect (X-linked) and aquaporin defect (autosomal recessive and dominant).Best Pract Res Clin Endocrinol Metab. 2016 Mar;30(2):263-76. doi: 10.1016/j.beem.2016.02.010. Epub 2016 Mar 2. Best Pract Res Clin Endocrinol Metab. 2016. PMID: 27156763 Review.
-
Nephrogenic diabetes insipidus.Annu Rev Physiol. 2001;63:607-30. doi: 10.1146/annurev.physiol.63.1.607. Annu Rev Physiol. 2001. PMID: 11181969 Review.
-
Vasopressin receptor mutations causing nephrogenic diabetes insipidus.Proc Assoc Am Physicians. 1998 Sep-Oct;110(5):387-94. Proc Assoc Am Physicians. 1998. PMID: 9756088 Review.
Cited by
-
Pharmacoperones: a new therapeutic approach for diseases caused by misfolded G protein-coupled receptors.Recent Pat Endocr Metab Immune Drug Discov. 2011 Jan;5(1):13-24. doi: 10.2174/187221411794351851. Recent Pat Endocr Metab Immune Drug Discov. 2011. PMID: 22074574 Free PMC article. Review.
-
Nephrogenic diabetes insipidus (NDI): clinical, laboratory and genetic characterization of five Brazilian patients.Clinics (Sao Paulo). 2009 May;64(5):409-14. doi: 10.1590/s1807-59322009000500007. Clinics (Sao Paulo). 2009. PMID: 19488606 Free PMC article.
-
Metformin, an AMPK activator, stimulates the phosphorylation of aquaporin 2 and urea transporter A1 in inner medullary collecting ducts.Am J Physiol Renal Physiol. 2016 May 15;310(10):F1008-12. doi: 10.1152/ajprenal.00102.2016. Epub 2016 Mar 9. Am J Physiol Renal Physiol. 2016. PMID: 26962099 Free PMC article.
-
A phenotypic high throughput screening assay for the identification of pharmacoperones for the gonadotropin releasing hormone receptor.Assay Drug Dev Technol. 2014 May;12(4):238-46. doi: 10.1089/adt.2014.576. Assay Drug Dev Technol. 2014. PMID: 24831790 Free PMC article.
-
Wnt5a induces renal AQP2 expression by activating calcineurin signalling pathway.Nat Commun. 2016 Nov 28;7:13636. doi: 10.1038/ncomms13636. Nat Commun. 2016. PMID: 27892464 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Miscellaneous